Gate2Brain is underway! The sixth @IRBBarcelona spin off, founded by #MeritxellTeixidó, has been launched with the “key” to transporting drugs into the brain and improving their effectiveness.
"We are very proud that nearly 15 years of research at #IRBBarcelona bear fruit and have brought about a new spin-off as promising as Gate2Brain", says director #FrancescPosas.
(2/3)
“The company launch today is the result of the collective success of the research groups and Innovation departments, which I want to thank for their work. We have worked shoulder to shoulder during all this time to finally make the company a reality" Teixidó adds.
(3/3)
• • •
Missing some Tweet in this thread? You can try to
force a refresh
🔬An international consortium, led by #IRBBarcelona & the biotech company @MerusNV, reports the discovery of MCLA-158, the first clinical candidate screened in #organoids targeting 🎯 #cancer#stemcells of solid tumors.
Named Petosemtamab, the antibody MCLA-158 prevents the onset of #metastasis (that is, the spread of #cancer to other vital organs) and slows the growth of primary tumours in experimental models of cancer.
The study also lays the groundwork for the use of #organoids in the #DrugDiscovery process undertaken by pharmaceutical companies.
Organoids are patient-derived samples that can be grown in the laboratory, and they reproduce certain aspects of the tumour compartment.
#IRBScience: Published in @GenomeMedicine, the latest work from the SBNB lab points to the co-occurrence of #cancer driver genes as a key to precision medicine.
The system is called Targeted Cancer Therapy for You (TCT4U), and it's aimed at predicting tumour response to different treatments.💊
It has allowed the identification of a set of complex biomarkers🧬that have now been made available to the medical-scientific community.
(2/4)↘️
"The sum of two or more mutated #Cancer driver genes affects the tumour's response to treatments" says @ptck72, "through this work, we see that studying cancer driver genes as a whole can bring about a great advance towards precision medicine".
@Eduard_puig is one of the committed scientists who recently made an important contribution to the field.
(1/4)
In June, @Eduard_puig, @SoniaCiudad and Natalia Carulla, among others, revealed the specific ensembles of Aβ protein that have the capacity to disrupt the membrane of neurons, causing their death.
@IRBBarcelona coordinates the European Project Evomet to train 15 young scientists and future leaders in metastasis research with the aim to identify therapeutic solutions. The project has received €4 M and will last for four years.
Each of the institutions will host one of the selected young researchers and will train them until they complete their doctorate, except for @IRBBarcelona and @idibell_cat IDIBELL, which will host two predoctoral researchers each.
#IRBScience: The @bbglab publishes "A compendium of mutational cancer driver genes" in @NatureRevCancer, with mportant implications in clinical decision making.
📢568 genes identified with the potential to trigger #cancer!
The study stands on the analysis of the genomes of 28,000 tumours from 66 types of cancer and it's a major update of the #IntOGen platform (intogen.org), aimed at identifying mutational cancer driver genes.
(2/5)
“The compendium of driver genes provides cancer researchers, both in the clinical and basic research setting, with crucial knowledge and it has an important impact on clinical decision-making,” says @nlbigas, head of the @bbglab at @IRBBarcelona and @icreacommunity.